Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Upadacitinib in Crohn's Disease (M13-740 Extension)
2015-003759-23Phase 2Active
- Sponsor
- AbbVie Inc.
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of upadacitinib in Crohn's disease, sponsored by AbbVie Inc. Primary endpoint: Clinical remission over time. Started May 2016; status: active.
02
Drugs
upadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2015-003759-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003759-23.